Love Employee/iStock via Getty Images Investors Should Know: The GLP-1 and broader metabolic disease drug space is advancing rapidly, with next-generation oral formulations, triple-acting compounds,… [+161 chars]Read More
As the GLP1 race heats up how can investors position themselves for the next wave of innovation LLYNYSE Seeking Alpha
